Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.

Abstract: A liquid crystal nanoparticle (LCNP)-based system allows for the encapsulation and targeted delivery of Zinc (II) phthalocyanine (ZnPC) to the plasma membrane bilayer of living cells for photodynamic therapy (PDT). The formulation comprises LCNPs that are loaded in their hydrophobic core with perylene (PY) and ZnPC. In embodiments, the LCNP surface is functionalized with Poly(ethylene glycol)-cholesterol conjugates (PEG-Chol) and/or another material enabling targeting the particle to the cellular membrane. This can improve cell killing via reactive oxygen species (ROS) generation as it allows for the localized ROS-mediated peroxidation of lipids in the membrane bilayer.

Abstract: Disclosed herein are compositions and methods for inhibiting viral entry.

Abstract: Various embodiments of bulking or cushioning agents or material and related medical devices and methods are disclosed. For example, a method of performing a medical procedure in a tract of a body may include injecting a material in a liquid phase proximate a target site between a first tissue layer and a second tissue layer, allowing the material to transition from the liquid phase to the gel phase in response to a raise in temperature of the material to approximately at or above the predetermined temperature, and performing a surgical procedure on the target site. The material may have the liquid phase at temperatures below a predetermined temperature and a gel phase at temperature approximately at or above the predetermined temperature.

Abstract: The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture.

Abstract: A formulation for sustained release of an apoptosis inhibitor in the inner ear to protect from hearing loss, especially due to exposure to chemotherapy with drugs such as cisplatin. The formulation can be injected through a small gauge needle into the inner ear, where it gels to form a sustained release depot for controlled delivery of drug over a few days. In the preferred embodiment, the formulation includes a thermoresponsive sol-gel polymer such as POLOXAMER 407 and an apoptosis inhibitory agent, preferably an inhibitor of apoptotic protease activating factor-1 (APAF-1), in an effective amount to prevent hearing loss, for example, due to the administration of platinum-based chemotherapeutic agents. As demonstrated by the examples, the hydrogel provides sustained release of an apoptosis inhibitory agent, LPT99, an anti-apoptosis agent that inhibits apoptotic protease activating factor-1 (APAF-1), as well as safety and efficacy in in vitro and in vivo models.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: The present invention relates to the field of oligopeptide prodrugs that are intended for the treatment of cancer. The selectivity of these prodrugs requires the presence of an (oligo)peptidic moiety and/or a protective capping group to ensure the prod-rug stability in blood. It further in particular relates to the exemplary oligopeptidic moiety ALGP and to prodrugs comprising it. In particular it also relates to the capping group phosphonoacetyl and to prodrugs comprising this capping group.

Abstract: This present invention relates to a polymer of ?-glutamyl transpeptidase catalyzing hydrolysis-induced charge reversal. The polymer comprises a ?-glutamyl transpeptidase-responsive element represented by Formula (I). When the polymer is used as drug carrier for anticancer drug, it can have a long circulation time in the blood, and can realize a charge reversal from negatively charged or the neutral to positively charged around the tumor blood vessel region, so that the positively charged polymer effectively penetrates deep into the tumor tissue, fast entering into the tumor cells, and greatly improves the therapeutic effect of the drug on the tumor. This overcomes the problems of slow diffusion of traditional polymer drug carriers in tumors and weak interaction with tumor cells, and has great significance in the field of anticancer treatment in the medical field.

Abstract: Compositions include a labeling agent featuring a plurality of free labeling units, where each labeling unit includes at least one conjugating group for covalent bonding to a biological molecule, at least one metal chelating group, and a metal ion chelated by the at least one metal chelating group, where a percentage by weight of water in the composition is 10% or less.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Abstract: Techniques regarding the transportation and/or delivery of molecular cargo by exosomes are provided. For example, one or more embodiments described herein can comprise a molecule, which can comprise a chemically modified molecular cargo bonded to a surface biomolecule of an exosome. The surface biomolecule can be located on a bilayer membrane of the exosome opposite a cytoplasm of the exosome.

Abstract: The present invention relates to conjugate complexes, comprising at least one biological entity, at least one cargo moiety, and at least one effector moiety that is capable of converting, degrading, and/or modifying a given medium, wherein the at least one cargo moiety and the at least one effector moiety are directly or indirectly coupled to the biological entity. The present invention further relates to uses thereof and methods for facilitating the transport of a cargo moiety through a given medium.

Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.

Abstract: Disclosed is a (D331Y) PLA2G6 knockin mouse, which shows similar clinical symptoms to those of patients suffering from Parkinson's disease (PD), and begins to display early-onset cell death of dopaminergic neurons in its substantia nigra (SN), synucleinopathy, and tau pathology at the age of about 6 months, wherein the dopaminergic neurons exhibit mitochondrial structural abnormality and dysfunction. Treatment of the (D331Y) PLA2G6 knockin mouse with L-Dopa shows a good response. The (D331Y) PLA2G6 knockin mouse can be used as a platform for developing a medicament and method for treating PD.

Abstract: In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). In certain embodiments the “probes” comprise cleavable fluorophore-quencher pair linked by a cathepsin K (or other protease) peptide substrate and tethered to a bisphosphonate. Unlike existing probes that are cleared within a few days in vivo, the probes described herein (e.g., OFS-1) allow for monitoring resorption over the course of longer time periods with a single dose.

Abstract: The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)-butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

Abstract: A bone biospecific agent comprises a contrast material core, which is visible using Magnetic Resonance Imaging (MRI) or Computed Tomography (CT). The contrast material core is surrounded by a polymeric shell, which is functionalised with a bone-targeting peptide. In use, the peptide targets the biospecific agent to bone. The bone biospecific agent can be used in diagnostic imaging techniques, such as MRI and CT, and in imaging bone remodelling activities, detecting and treating pathological bone conditions and/or bone repair processes. The invention extends to the diagnosis and/or treatment of bone disease and bone pathologies using the biospecific agents.

Abstract: The invention is directed to compositions comprising disassembled, stacked melanin oligomers, and methods of preparing and using such compositions.

Abstract: Methods for detecting ?-synuclein oligomers in vivo comprise administering an antibody to an individual suspected of carrying soluble ?-synuclein, wherein the antibody is produced from a stabilized soluble ?-synuclein oligomer and is capable of binding the stabilized soluble ?-synuclein oligomer, wherein the stabilized soluble ?-synuclein oligomer has a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the ?-synuclein, and wherein the antibody is labelled with a detectable marker; and detecting the presence of any complex formed between the antibody and soluble ?-synuclein by detection of the marker.

Abstract: A method of destroying pathogens disposed upon an epidermis includes providing a hand held device including a grip and a lamp, transmitting far-UVC light via the lamp, and filtering the transmitted far-UVC light to attenuate portions of transmitted UVC light that have a wavelength known to cause damage to an epidermis of a human. The epidermis is scanned by tracing the hand held device over a localized area of the epidermis thereby illuminating the localized area with the filtered far-UVC light. The filtered far-UVC light destroys pathogens disposed upon the epidermis while not causing adverse biological damage to the epidermis.

Abstract: An apparatus includes a fluid reservoir, a sterilization member, and a transfer adapter. The sterilization member operably couples to the fluid reservoir. The sterilization member is configured to be transitioned between a first configuration, in which the sterilization member obstructs an inlet surface of the fluid reservoir and maintains the inlet surface in a substantially sterile environment, and a second configuration, in which the inlet surface is unobstructed. The transfer adapter is configured to be placed in fluid communication with a portion of a patient. The transfer adapter is configured to move relative to the sterilization member from a first position to a second position such that a surface of the transfer adapter contacts the sterilization member to transition the sterilization member to the second configuration. The fluid reservoir is placed in fluid communication with the transfer adapter when the transfer adapter is in the second position.

Abstract: Embodiments of the disclosure include an uncovered ultraviolet light emitting panel for use in supporting instruments in an operating room. The panel fits inside an autoclave for sterilization and can be utilized without a sterile cover. In use, the panel irradiates surgical instruments and the nearby air continuously.

Abstract: A control panel having a variety of potential applications that utilize ultraviolet-C (UV-C) light as a means of disinfection. In one embodiment, a human/machine interface (HMI) panel, such as a touchscreen or keypad uses a dynamically moveable multi-reflector assembly using UV-C light to disinfect its touch surfaces. The goal of integrating UV-C disinfection with an HMI works to provide a safe and effective dose of UV-C light to the panel's surface for the purpose of reducing the number of active pathogens.

Abstract: A handheld portable device for sanitizing a surface or air surrounding a surface. The handheld portable device includes a body that comprises a user input and a UVC light source disposed at the body. The handheld portable device also includes a power source for providing power to the UVC light source. Responsive to actuating the user input, such as by a user holding the handheld portable device, the UVC light source emits UVC light to sanitize the surface or the air surrounding the surface of pathogens. The handheld portable device includes a visible light emitter that, when powered, emits visible light to indicate the surface or space that is irradiated by the UVC light.

Abstract: Certain exemplary embodiments of the present disclosure can provide an apparatus and method for generating at least one radiation can be provided. The exemplary apparatus and/or method can selectively kill and/or affect at least one virus. For example, a radiation source first arrangement can be provided which is configured to generate at least one radiation having one or more wavelengths provided in a range of about 200 nanometers (nm) to about 230 nm, and at least one second arrangement can be provided which is configured to prevent the at least one radiation from having any wavelength that is outside of the range can be provided or which can be substantially harmful to cells of the body.

Abstract: A gas delivery system (50) for delivering a flow of breathing gas to a patient (54) includes a blower assembly (100) structured to generate the flow of breathing gas. The blower assembly includes a gas flow path including an inlet manifold, an assembly (130) structured to adjust a pressure and/or flow rate of the flow of breathing gas, and an outlet manifold structured to be coupled to a patient circuit. The gas delivery system additionally includes a light system structured to generate sanitizing light and deliver the sanitizing light to one or more internal surfaces of at least one of the inlet manifold, the assembly and the outlet manifold for sanitizing the one or more internal surfaces.

Abstract: Automatic timer for air conditioning condensate water chemical dispenser. This timer regulate automatically the time when chemicals are needed.

Abstract: Various implementations of the invention are directed toward a sanitizing door handle and/or components of such sanitizing door handle. Some implementations of the invention are directed toward a manual sanitizing door handle while some implementations of the invention are directed toward an auto-sanitizing door handle. According to some implementations of the invention, a sanitizing fluid is dispensed directly onto an exterior surface of the sanitizing door handle in connection with an operation of the door handle to sanitize the door handle. According to some implementations of the invention, a sanitizing fluid is dispensed directly onto a user's hand(s) in connection with an operation of the door handle to sanitize the user's hand(s).

Abstract: The disclosure herein concerns a method including receiving at a computer at least one target value of a scent parameter for an environment that is remote from the computer, receiving at the computer a sensed parameter of the environment, and controlling, via the computer, diffusion of a liquid from a source of the liquid in fluid communication with at least one scent diffusion device to achieve the target value of the scent parameter, wherein controlling includes setting or adjusting an operation parameter of the at least one scent diffusion device in response to the sensed parameter.

Abstract: A wound dressing is which has haemostatic, coagulation-promoting and biocidal properties and can therefore be utilized particularly for acute wound care. Typical areas of application for acute wound care are, for example, the treatment of gunshot wounds. The wound dressing features selected halloysites which, for example, are applied to textile fibers or non-woven materials.

Abstract: This invention is directed to a multi-layered tissue graft comprising a collagen layer and at least one separated and washed placental tissue component and/or umbilical cord component, wherein the collagen is human collagen substantially free of non-human antigens.

Abstract: Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.

Abstract: A surgical joint replacement kit including a first joint replacement component and a surgical sealant. The first joint replacement component is capable of being implanted to replace a joint between a first bone and a second bone. The first bone is cut in conjunction with implanting the first joint replacement component. Cutting the first bone causes a bodily fluid to flow from the first bone. The surgical sealant includes an electrospun dextran base and an effective amount of at least one of fibrinogen and thrombin. The at least one of fibrinogen and thrombin is applied to the electrospun dextran base to form the surgical sealant. The surgical sealant is capable of staunching the flow of the bodily fluid from the first bone.

Abstract: The inventive subject matter provides compositions and methods for transiently or permanently treating or managing an injury. Contemplated compositions are polymerizable in situ over short time periods, even in the presence of blood, without undue exothermic heat. Contemplated compositions may further comprise an anesthetic, an antiseptic, an adhesion promoter, and/or a vasoconstrictor.

Abstract: Implant devices are coated with biologically active compounds, in particular with plant extracts from vinification residues. The implant devices are bone implants, and in particular dental implants. A method for functionalizing a surface of an implant device is includes the steps of a) optionally, treating the surface of the implant device with air, oxygen, argon, nitrogen plasma, and plasma capable of removing the surface layer of hydrocarbon contamination, b) treating the surface of the implant with an amine substrate, c) treating the surface of the implant resulting from step b), alternatively with a marcs extract, and drying the functionalized surface, or by co-adsorbing a marcs extract and hyaluronic acid, and drying the functionalized surface, or by adsorbing hyaluronic acid and post-adsorbing a marcs extract, and drying of the functionalized surface.

Abstract: To provide a medical device including a substrate and a hydrophilic polymer layer formed on at least a part of the substrate, which satisfies the following conditions (a) to (d): (a) a polymer constituting the hydrophilic polymer layer is a hydrophilic polymer having an acidic group; (b) the hydrophilic polymer layer has a thickness of 1 nm or more and less than 100 nm; (c) a number ratio of basic group/acidic group of the hydrophilic polymer layer is 0.2 or less; and (d) a liquid film retention time at 40 minutes after ultrasonic cleaning in a phosphate buffer solution is 15 seconds or more. The present invention provides a medical device in which a surface of a substrate is hydrophilized, and a method for manufacturing same by a simple method.

Abstract: The present invention belongs to the field of biomedicine and tissue engineering. Specifically, it relates to a biomaterial and to an in vitro method for preparing a tissue or bioartificial membrane having controlled elasticity and rigidity, and to the tissue or artificial membrane obtainable using the method. The invention further relates to the uses thereof in medicine.

Abstract: The invention features a system for preparing composite collagen microfiber scaffolds and biomaterials with a broad range of mechanical properties and uses. Using low cost materials, rapid fabrication techniques, and accessible software tools, the system provides a customizable, automated, biomaterial fabrication platform with broad accessibility.

Abstract: The invention is related to a method for creating coating for medical implantable devices placed inside the recipient's body and having at least one surface contacting with blood, in particular, on blood vessel prostheses made of a polymeric material (polyethylene terephthalate), in order to activate the endothelization process and prevent thrombosis. For this purpose, the specified method is characterized by the alternation of stages of ion etching with spray coating. The proposed method allows to create a discontinuous coating on a polymer vascular prosthesis made of polyethylene terephthalate, characterized by low thrombogenicity.

Abstract: To provide a bioimplant capable of controlling a rate of an antibacterial agent and an antibiotic to be eluted from the coating film. An evanescent coating film made of a calcium phosphate-based material having crystallinity of 10% to 90% is formed at a predetermined area of the bioimplant and an antibacterial agent or an antibiotic is contained in the coating film to suppress adhesion of bacteria.

Abstract: A xenograft for treating a tendon or ligament condition in a subject, wherein said xenograft comprises at least a portion of a macropod tendon.

Abstract: The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.

Abstract: The invention disclosed herein relates to compositions for coating a surface to provide a release of antimicrobial active agents from said surface, to coatings formed using said compositions, and to medical devices comprising said coatings.

Abstract: The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty. More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the site of intervention. The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12.

Abstract: An implantable apparatus, including at least one corrodible zinc-containing portion, where a content range of zinc in the at least one zinc-containing portion is [30, 50) wt. % and zinc in the zinc-containing portion is an amorphous structure, or a content range of zinc in the at least one zinc-containing portion is [50, 70] wt. %, and a microscopic structure of zinc in the zinc-containing portion is at least one of an amorphous structure, a non-equiaxed structure, an ultrafine-grained structure, or an equiaxed structure with a grain size number of 7 to 14, or a content range of zinc in the at least one zinc-containing portion is (70, 100] wt. % and a microscopic structure of zinc in the zinc-containing portion is at least one of a non-equiaxed structure, an ultrafine-grained structure, or an equiaxed structure with a grain size number of 7 to 14.

Abstract: The present invention relates to biomaterials coated with an active agent eluting coating, wherein implantation of the coated biomaterial results in reduced implant-related complications and/or improved integration of the biomaterial into the host tissue and further relates to kits containing the coated biomaterial. The present invention also relates to methods and kits for coating the biomaterial. It is based, at least in part, on the discovery that biomaterial coated with a cytokine eluting coating resulted in the shift of early stage macrophage polarization that were associated with positive long-term effects such as minimized capsule formation and improved tissue quality and composition as compared to uncoated biomaterials.

Abstract: An absorbable iron-based alloy implantable medical device, including an iron-based alloy substrate and a degradable polymer coating and a zinc-containing protector which are arranged on the surface of the iron-based alloy substrate. The zinc-containing protector is selected from zinc and/or a zinc alloy, or a mixture of zinc and/or a zinc alloy and a degradable binder. The weight percentage of the zinc and/or zinc alloy in the mixture is greater than or equal to 20% and less than 100%. The zinc-containing protector is capable of delaying the corrosion of the iron-based alloy substrate during the early stage of implantation, such that the iron-based alloy substrate essentially avoids corrosion during the early stage of implantation and the clinical mechanical property requirements for the device in the early stage of implantation can be satisfied.

Abstract: A medical device substrate with a coating including a functional layer located on the substrate, with the functional layer including at least one sugar alcohol and being bonded to the substrate directly or indirectly via a functionalization of the sugar alcohol. Alternatively, the functional layer may also include other saccharides, in which case it is essential that polymerization of the saccharides takes place only upon bonding to the substrate. The inventive medical device exhibits reduced platelet adhesion and aggregation.